查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球功效測試市場：按服務類型（抗菌和防腐效果測試、殺菌效果測試）、按應用（製藥、化妝品和個人護理產品、醫療器械、消費品）、按地區 - 到 2027 年預測
市場調查報告書
商品編碼
1105262

全球功效測試市場：按服務類型（抗菌和防腐效果測試、殺菌效果測試）、按應用（製藥、化妝品和個人護理產品、醫療器械、消費品）、按地區 - 到 2027 年預測

Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027
出版日期: | 出版商: MarketsandMarkets | 英文 176 Pages | 訂單完成後即時交付

價格
簡介目錄

全球療效試驗市場規模將從 2022 年的 3.15 億美元到 2027 年達到 4.23 億美元，在預測期內以 6.1% 的複合年增長率增長。

這一市場增長的主要驅動力是表面消毒劑和防腐劑在污染控制和產品穩定性方面的使用越來越多，以及藥效測試外包（主要在製藥、生物製藥和化妝品行業），以及越來越多的採用的 QbD 方法。新興市場的高增長潛力預計將為在功效試驗市場上運營的公司提供增長機會。

“按服務類型來看，常規檢測在抗菌防腐效果檢測市場中佔比最大”

傳統測試通常需要在很長一段時間內在多個測試點進行微生物檢測。試用期通常從最少 28 天到 12 週或更長時間不等。執行檢測不需要特殊設備或培訓，因為它涉及標準微生物技術，類似於長期一般挑戰方案中使用的技術。事實上，這種加速雙重挑戰 (ADC) 測定目前在許多實驗室中以其基本形式或用於各種應用的變體形式使用。

“按應用來看，醫藥製造板塊在預測期內將呈現最高增長率”

按應用，功效測試市場細分為藥品製造應用、化妝品和個人護理產品應用、消費品應用和醫療設備應用。 2021 年，製藥應用□□是市場上最大的產品部分。這一市場增長可歸因於主要製藥公司增加研發製造、政府支持、製藥行業的增長以及對患者安全的關注。

“預計亞太市場將在預測期內（2020-2027 年）呈現最高增長率”

預計亞太市場在預測期內將以最高的複合年增長率增長。這主要是由於政府醫療保健支出增加、老年人口不斷增長、消費者健康意識提高以及慢性病發病率上升，所有這些都是該地區藥品增長的原因。在中國建立生產設施的製藥公司數量

“北美：功效測試市場份額最大”

北美在功效測試市場中佔有最大份額。該地區擁有成熟的製藥行業，諸如高研發成本、大型服務提供商的存在以及該地區製藥和化妝品公司增加分析測試（包括功效測試）外包等因素是市場增長的主要驅動力。

內容

第1章介紹

第2章研究方法

第 3 章執行摘要

第 4 章重要注意事項

第 5 章市場概述

  • 簡介
  • 市場動態
    • 驅動程序
    • 約束因素
    • 機會
    • 任務
  • 監管分析
  • COVID-19 對功效測試服務的影響
  • 價格分析
  • 專利分析
  • 貿易分析
  • 價值鏈分析
  • 生態系統分析
  • 波特五力分析
  • 技術分析

第 6 章功效測試市場：按服務類型劃分

  • 簡介
  • 殺菌效果測試
    • 表面測試
    • 暫停測試
  • 抗菌防腐效果測試
    • 常規
    • 快速型

第 7 章。功效測試市場：按應用分類

  • 簡介
  • 製藥業
  • 化妝品和個人護理產品
  • 消費品
  • 醫療設備

第 8 章。功效研究市場：按地區劃分

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他
  • 其他地區
    • 拉丁美洲
    • 中東和非洲

第 9 章競爭格局

  • 概覽
  • 主要企業戰略/領先企業
  • 市場份額分析
  • 主要市場參與者的收入份額分析
  • 企業評估象限
  • 企業評估象限：初創企業/中小企業
  • 企業足跡分析
  • 競爭場景

第 10 章公司簡介

  • 功效檢測服務商
    • EUROFINS SCIENTIFIC
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • WUXI APPTEC
    • SGS SA
    • INTERTEK GROUP PLC
    • MICROCHEM LABORATORY
    • ACCUGEN LABORATORIES, INC.
    • PACIFIC BIOLABS
    • NORTH AMERICAN SCIENCE ASSOCIATES
    • TOXIKON
    • BIOSCIENCE LABORATORIES, INC.
    • CONSUMER PRODUCT TESTING COMPANY (CPTC)
    • ALMAC GROUP
    • MSL SOLUTION PROVIDERS
    • NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY)
    • ALS LIMITED
    • ABBOTT ANALYTICAL
    • BLUTEST LABORATORIES LIMITED
    • LUCIDEON
    • HELVIC LABORATORIES (A TENTAMUS COMPANY)
  • 殺菌劑製造商
    • PROCTER & GAMBLE
    • THE CLOROX COMPANY
    • 3M
    • RECKITT BENCKISER GROUP PLC
    • ECOLAB
    • STERIS
    • CANTEL MEDICAL
    • DIVERSEY HOLDINGS LTD.
    • CARROLLCLEAN
    • PAUL HARTMANN AG

第11章 附錄

簡介目錄
Product Code: BT 5932

The global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period. The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach. The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market.

"By method type, the traditional test method accounted for the largest share of the antimicrobial/preservative testing market"

Traditional testing methods generally require microbial assays at multiple test points over extended periods of time. Test durations typically range from a minimum of 28 days to 12 or more weeks. Because standard microbiological techniques similar to those employed in longer-term generic challenge protocols are involved, no special equipment or training is necessary to perform the assay. In fact, this accelerated double challenge (ADC) assay is currently being used in its basic form or in variations at numerous laboratories for a variety of applications.

"The pharmaceutical manufacturing application segment will grow at the highest rate during the forecast period."

On the basis of application, the efficacy testing market is segmented into pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications. In 2021, pharmaceutical manufacturing applications were the largest product segment in the market. Growth in this market can be attributed to the increasing R&D manufactures by leading pharmaceutical companies, government support, growth of the pharmaceutical industry, and a growing focus on patient safety.

"The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020-2027)."

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing government expenditure on healthcare, rising geriatric population, growing consumer health awareness, increasing incidence of chronic diseases thereby being responsible for the growth of pharmaceutical products in this region, and the increasing number of pharmaceutical companies that are establishing manufacturing facilities in APAC countries.

"North America: the largest share of the efficacy testing market"

North America accounted for the largest share of the efficacy testing market. Factors such as the presence of a well established pharmaceutical industry in the region, the high R&D expenditure, a strong presence of major service providers, and rising outsourcing of analytical testing (including efficacy testing) by pharmaceutical and cosmetic companies in the region are the major factors driving the market growth.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

  • By Respondent- Supply Side- 80%, Demand Side-20%
  • By Designation- Executives- 25%, CXOs- 20%, Managers - 55%
  • By Region- North America - 50%, Europe - 20%, APAC - 20%, RoW- 10%

The key players operating in the efficacy testing market are Charles River Laboratories (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek Group (UK), Nelson Laboratories, LLC (a Sotera Health company, US), Microbac Laboratories, Inc. (US), Almac Group (UK), North American Science Associates, Inc. (US), Toxikon (US), Pacific Biolabs (US), MSL Solution Providers (UK), Intertek Group PLC (UK), Accugen Laboratories, Inc. (US), Consumer Product Testing Company (US), Lucideon (UK), BioScience Laboratories, Inc. (US), ALS Limited (Australia), Microchem Laboratory (US), Oxford Biosciences Ltd. (UK), Abbott Analytical (Australia), Helvic Laboratories (a Tentamus Company, UK), Honeyman Group Limited (UK), Danish Technological Institute (DTI, Denmark), and BluTest Laboratories Limited (UK).

Research Coverage:

The report segments the efficacy testing market based on region (Asia Pacific, Europe, North America, and RoW), service type (disinfectant efficacy testing and antimicrobial/preservative efficacy testing), application (pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications).

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the efficacy testing market

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the efficacy testing market and provides them information on key market drivers, challenges, and opportunities.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the efficacy testing market. The report analyzes the market based on the service type, application, and region.
  • Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and service/product launches in the efficacy testing market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of efficacy testing solutions across regions.
  • Market Diversification: Exhaustive information about products/ services, untapped regions, recent developments, and investments in the efficacy testing market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the efficacy testing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primary sources
    • FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 3 EFFICACY TESTING MARKET: FINAL CAGR PROJECTIONS
    • FIGURE 4 EFFICACY TESTING MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 5 EFFICACY TESTING MARKET: SEGMENTAL ASSESSMENT
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET RANKING ANALYSIS
  • 2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 EFFICACY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 REGIONAL SNAPSHOT OF EFFICACY TESTING MARKET

4 PREMIUM INSIGHTS

  • 4.1 EFFICACY TESTING MARKET OVERVIEW
    • FIGURE 10 GROWING PREFERENCE FOR OUTSOURCING EFFICACY TESTING TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: EFFICACY TESTING MARKET, BY APPLICATION AND COUNTRY (2021)
    • FIGURE 11 PHARMACEUTICAL MANUFACTURING APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF EFFICACY TESTING MARKET
    • FIGURE 12 CHINA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027
  • 4.4 EFFICACY TESTING MARKET, BY REGION
    • FIGURE 13 NORTH AMERICA TO DOMINATE MARKET IN 2027
  • 4.5 EFFICACY TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 EFFICACY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability
        • 5.2.1.1.1 Growing focus on contamination control
        • 5.2.1.1.2 Increasing concerns over product stability
      • 5.2.1.2 Growing preference for outsourcing efficacy testing
      • 5.2.1.3 Rising adoption of quality by design approach
      • 5.2.1.4 Stringent regulations for use of surface disinfectants
      • 5.2.1.5 Growing awareness of sanitization and hygiene due to spread of COVID-19
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adverse effects of chemical disinfectants
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging countries in Asia Pacific
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Time-consuming process
  • 5.3 REGULATORY ANALYSIS
    • 5.3.1 DISINFECTANT EFFICACY TESTING
    • 5.3.2 ANTIMICROBIAL EFFICACY TESTING
  • 5.4 IMPACT OF COVID-19 ON EFFICACY TESTING SERVICES
  • 5.5 PRICING ANALYSIS
    • TABLE 1 PRICE OF SURFACE DISINFECTANT PRODUCTS (2022)
  • 5.6 PATENT ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 TRADE ANALYSIS FOR DISINFECTANTS
    • TABLE 2 IMPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 3 EXPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.8 VALUE CHAIN ANALYSIS
    • FIGURE 16 VALUE CHAIN ANALYSIS: EFFICACY TESTING MARKET
  • 5.9 ECOSYSTEM ANALYSIS
    • FIGURE 17 SURFACE DISINFECTANTS MARKET: ECOSYSTEM ANALYSIS
    • TABLE 4 ROLE IN ECOSYSTEM
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 EFFICACY TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF BUYERS
    • 5.10.4 BARGAINING POWER OF SUPPLIERS
    • 5.10.5 DEGREE OF COMPETITION
  • 5.11 TECHNOLOGY ANALYSIS

6 EFFICACY TESTING MARKET, BY SERVICE TYPE

  • 6.1 INTRODUCTION
    • TABLE 6 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
  • 6.2 DISINFECTANT EFFICACY TESTING
    • TABLE 7 DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 8 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 9 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 12 DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • 6.2.1 SURFACE TEST METHOD
      • 6.2.1.1 Surface test method segment to account for larger share of disinfectant efficacy testing market
    • TABLE 13 SURFACE TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 NORTH AMERICA: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 EUROPE: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 APAC: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.2 SUSPENSION TEST METHOD
      • 6.2.2.1 Suspension test method is typically performed by researchers during development stage of disinfectants
    • TABLE 17 SUSPENSION TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 18 NORTH AMERICA: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 19 EUROPE: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 APAC: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING
    • TABLE 21 EUROFINS SCIENTIFIC AET TEST PROTOCOL
    • TABLE 22 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 23 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 24 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 25 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 27 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • 6.3.1 TRADITIONAL TEST METHOD
      • 6.3.1.1 Traditional test method segment to dominate AET/PET market
    • TABLE 28 TRADITIONAL TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 RAPID TEST METHOD
      • 6.3.2.1 Regulatory uncertainties restraining adoption of rapid microbial methods
    • TABLE 29 RAPID TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)

7 EFFICACY TESTING MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 30 EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 7.2 PHARMACEUTICAL MANUFACTURING APPLICATIONS
    • 7.2.1 INCREASING FOCUS ON ENSURING QUALITY OF DRUGS TO DRIVE SEGMENT GROWTH
    • TABLE 31 EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 32 NORTH AMERICA: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 EUROPE: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 34 APAC: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS
    • 7.3.1 EFFICACY TESTING IS AN ESSENTIAL PART OF STABILITY TESTING REGIMEN OF COSMETICS
    • TABLE 35 EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 36 NORTH AMERICA: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 EUROPE: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 APAC: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 CONSUMER PRODUCT APPLICATIONS
    • 7.4.1 GROWING FOCUS ON HEALTHY ENVIRONMENT IN HOMES AND INDUSTRIAL FACILITIES TO DRIVE SEGMENT GROWTH
    • TABLE 39 EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 EUROPE: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 APAC: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 MEDICAL DEVICE APPLICATIONS
    • 7.5.1 IMPOSITION OF STRINGENT GOVERNMENT REGULATIONS TO DRIVE SEGMENT GROWTH
    • TABLE 43 EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 44 NORTH AMERICA: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 EUROPE: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 46 APAC: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

8 EFFICACY TESTING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 47 EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 18 NORTH AMERICA: EFFICACY TESTING MARKET SNAPSHOT
    • TABLE 48 NORTH AMERICA: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 NORTH AMERICA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 50 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 52 NORTH AMERICA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 US to dominate North American efficacy testing market during forecast period
    • TABLE 53 US: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 US: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 55 US: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Government initiatives to drive market growth in Canada
    • TABLE 56 CANADA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 57 CANADA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 58 CANADA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 59 EUROPE: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 60 EUROPE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Germany to account for largest share in European market
    • TABLE 64 GERMANY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 65 GERMANY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 66 GERMANY: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.2 FRANCE
      • 8.3.2.1 High demand for cosmetics in France to drive market growth
    • TABLE 67 FRANCE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 FRANCE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 69 FRANCE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.3 UK
      • 8.3.3.1 Efficacy testing market in UK is primarily driven by enforcement of regulatory and industry standards
    • TABLE 70 UK: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 UK: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 72 UK: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Increasing pharmaceutical production in Italy to drive market growth
    • TABLE 73 ITALY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 ITALY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 75 ITALY: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.5 SPAIN
      • 8.3.5.1 Rising R&D expenditure to boost market growth in Spain
    • TABLE 76 SPAIN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 77 SPAIN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 78 SPAIN: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 79 ROE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 80 ROE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 81 ROE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 19 ASIA PACIFIC: EFFICACY TESTING MARKET SNAPSHOT
    • TABLE 82 APAC: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 83 APAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 85 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 86 APAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 China to dominate Asia Pacific market
    • TABLE 87 CHINA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 88 CHINA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 89 CHINA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.2 JAPAN
      • 8.4.2.1 Rising R&D investments to drive market growth in Japan
    • TABLE 90 JAPAN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 91 JAPAN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 92 JAPAN: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 Growing pharmaceutical industry in India to drive market growth
    • TABLE 93 INDIA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 94 INDIA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 95 INDIA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.4 REST OF ASIA PACIFIC
    • TABLE 96 ROAPAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 ROAPAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 98 ROAPAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.5 REST OF THE WORLD
    • TABLE 99 ROW: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 100 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 101 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 102 ROW: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 103 ROW: EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 8.5.1 LATIN AMERICA
      • 8.5.1.1 Increasing pharmaceutical R&D expenditure to drive market growth in Latin America
    • TABLE 104 LATAM: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 LATAM: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.5.2 MIDDLE EAST AND AFRICA
      • 8.5.2.1 UAE has emerged as key market in MEA region
    • TABLE 106 MEA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 107 MEA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 20 KEY DEVELOPMENTS IN EFFICACY TESTING MARKET, 2019-2022
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 21 EFFICACY TESTING MARKET SHARE, BY KEY PLAYER, 2021
    • TABLE 108 EFFICACY TESTING MARKET: DEGREE OF COMPETITION
  • 9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 9.5 COMPANY EVALUATION QUADRANT
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
  • 9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 9.6.1 PROGRESSIVE COMPANIES
    • 9.6.2 STARTING BLOCKS
    • 9.6.3 RESPONSIVE COMPANIES
    • 9.6.4 DYNAMIC COMPANIES
  • 9.7 FOOTPRINT ANALYSIS OF COMPANIES
    • 9.7.1 SERVICE FOOTPRINT OF COMPANIES
    • TABLE 109 SERVICE FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021)
    • 9.7.2 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 110 REGIONAL FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021)
  • 9.8 COMPETITIVE SCENARIO
    • TABLE 111 PRODUCT LAUNCHES
    • TABLE 112 DEALS
    • TABLE 113 OTHER DEVELOPMENTS

10 COMPANY PROFILES

  • 10.1 EFFICACY TESTING SERVICE PROVIDERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 10.1.1 EUROFINS SCIENTIFIC
    • TABLE 114 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 25 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
    • 10.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • TABLE 115 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
    • FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
    • 10.1.3 WUXI APPTEC
    • TABLE 116 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 27 WUXI APPTEC: COMPANY SNAPSHOT (2021)
    • 10.1.4 SGS SA
    • TABLE 117 SGS SA: BUSINESS OVERVIEW
    • 10.1.5 INTERTEK GROUP PLC
    • TABLE 118 INTERTEK GROUP PLC: BUSINESS OVERVIEW
    • FIGURE 28 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021)
    • 10.1.6 MICROCHEM LABORATORY
    • TABLE 119 MICROCHEM LABORATORY: BUSINESS OVERVIEW
    • 10.1.7 ACCUGEN LABORATORIES, INC.
    • TABLE 120 ACCUGEN LABORATORIES, INC.: BUSINESS OVERVIEW
    • 10.1.8 PACIFIC BIOLABS
    • TABLE 121 PACIFIC BIOLABS: BUSINESS OVERVIEW
    • 10.1.9 NORTH AMERICAN SCIENCE ASSOCIATES
    • TABLE 122 NORTH AMERICAN SCIENCE ASSOCIATES: BUSINESS OVERVIEW
    • 10.1.10 TOXIKON
    • TABLE 123 TOXIKON: BUSINESS OVERVIEW
    • 10.1.11 BIOSCIENCE LABORATORIES, INC.
    • TABLE 124 BIOSCIENCE LABORATORIES, INC.: BUSINESS OVERVIEW
    • 10.1.12 CONSUMER PRODUCT TESTING COMPANY (CPTC)
    • TABLE 125 CONSUMER PRODUCT TESTING COMPANY (CPTC): BUSINESS OVERVIEW
    • 10.1.13 ALMAC GROUP
    • TABLE 126 ALMAC GROUP: BUSINESS OVERVIEW
    • 10.1.14 MSL SOLUTION PROVIDERS
    • TABLE 127 MSL SOLUTION PROVIDERS: BUSINESS OVERVIEW
    • 10.1.15 NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY)
    • TABLE 128 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW
    • 10.1.16 ALS LIMITED
    • TABLE 129 ALS LIMITED: BUSINESS OVERVIEW
    • 10.1.17 ABBOTT ANALYTICAL
    • TABLE 130 ABBOTT ANALYTICAL: BUSINESS OVERVIEW
    • 10.1.18 BLUTEST LABORATORIES LIMITED
    • TABLE 131 BLUTEST LABORATORIES LIMITED: BUSINESS OVERVIEW
    • 10.1.19 LUCIDEON
    • TABLE 132 LUCIDEON: BUSINESS OVERVIEW
    • 10.1.20 HELVIC LABORATORIES (A TENTAMUS COMPANY)
    • TABLE 133 HELVIC LABORATORIES: BUSINESS OVERVIEW
  • 10.2 MANUFACTURERS OF DISINFECTANTS
    • 10.2.1 PROCTER & GAMBLE
    • TABLE 134 PROCTER & GAMBLE: BUSINESS OVERVIEW
    • FIGURE 29 PROCTER & GAMBLE: COMPANY SNAPSHOT (2021)
    • 10.2.2 THE CLOROX COMPANY
    • TABLE 135 THE CLOROX COMPANY: BUSINESS OVERVIEW
    • FIGURE 30 THE CLOROX COMPANY: COMPANY SNAPSHOT (2021)
    • 10.2.3 3M
    • TABLE 136 3M: BUSINESS OVERVIEW
    • FIGURE 31 3M: COMPANY SNAPSHOT (2021)
    • 10.2.4 RECKITT BENCKISER GROUP PLC
    • TABLE 137 RECKITT BENCKISER GROUP PLC: BUSINESS OVERVIEW
    • FIGURE 32 RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT (2021)
    • 10.2.5 ECOLAB
    • TABLE 138 ECOLAB: BUSINESS OVERVIEW
    • FIGURE 33 ECOLAB: COMPANY SNAPSHOT (2021)
    • 10.2.6 STERIS
    • TABLE 139 STERIS: BUSINESS OVERVIEW
    • FIGURE 34 STERIS: COMPANY SNAPSHOT (2021)
    • 10.2.7 CANTEL MEDICAL
    • TABLE 140 CANTEL MEDICAL: BUSINESS OVERVIEW
    • FIGURE 35 CANTEL MEDICAL: COMPANY SNAPSHOT (2021)
    • 10.2.8 DIVERSEY HOLDINGS LTD.
    • TABLE 141 DIVERSEY HOLDINGS LTD.: BUSINESS OVERVIEW
    • FIGURE 36 DIVERSEY HOLDINGS LTD.: COMPANY SNAPSHOT (2021)
    • 10.2.9 CARROLLCLEAN
    • TABLE 142 CARROLLCLEAN: BUSINESS OVERVIEW
    • 10.2.10 PAUL HARTMANN AG
    • TABLE 143 PAUL HARTMANN AG: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS